drugset / Trial / NCT00356447

Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.

NCT00356447

Phase 3 Completed 249 enrolled Bayer
RandomizedParallel-groupDouble-blindTreatment

Summary

The study evaluates in Chinese post-menopausal women the combination of drospirenone 2 mg and estradiol 1 mg for the treatment of climacteric symptoms, such as hot flushes (vasomotor symptoms) and uro-genital complaints.

Timeline

Start
2006-05
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Estradiol Other / unclassified 1 mg Oral
Comparator drospirenone Unknown 2 mg Oral

Indications